Strategic Treatment Optimization for HCV (STOPHCV1): a randomised controlled trial of ultrashort duration therapy for chronic hepatitis C

Graham S. Cooke, Sarah Pett, Leanne McCabe, Chris Jones, Richard Gilson, Sumita Verma, Stephen D Ryder, Jane D Collier, Stephen T. Barclay, Aftab Ala, Sanjay Bhagani, Mark Nelson, Chinlye Ch’Ng, Ben Stone, Martin Wiselka, Daniel Forton, Stuart McPherson, Rachel Halford, Dung Nguyen, David Smith, Azim Ansari, Emily Dennis, Fleur Hudson, Eleanor J Barnes, Ann Sarah Walker on behalf of the STOP-HCV trial team
doi: https://doi.org/10.1101/2021.01.22.21250208
Back to top
Posted January 26, 2021.
Download PDF

Supplementary Material

Data/Code
Email
Strategic Treatment Optimization for HCV (STOPHCV1): a randomised controlled trial of ultrashort duration therapy for chronic hepatitis C
Graham S. Cooke, Sarah Pett, Leanne McCabe, Chris Jones, Richard Gilson, Sumita Verma, Stephen D Ryder, Jane D Collier, Stephen T. Barclay, Aftab Ala, Sanjay Bhagani, Mark Nelson, Chinlye Ch’Ng, Ben Stone, Martin Wiselka, Daniel Forton, Stuart McPherson, Rachel Halford, Dung Nguyen, David Smith, Azim Ansari, Emily Dennis, Fleur Hudson, Eleanor J Barnes, Ann Sarah Walker
medRxiv 2021.01.22.21250208; doi: https://doi.org/10.1101/2021.01.22.21250208
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area